loading page

Transplacental transmission of SARS CoV-2 virus and antibodies in pregnant women and their new-borns according to the trimester of maternal infection: A French multicentre prospective study
  • +14
  • Louise Lucot-Royer,
  • Charline Bertholdt,
  • Solene Marty-Quinternet ,
  • Jean Paul Bory ,
  • Christine Devalland ,
  • Margaux Canaguier,
  • Camille Coppola ,
  • Marie-Laure Eszto ,
  • Edgar Montoya Ramirez,
  • Sandrine Reviron,
  • Didier Riethmuller,
  • Emma Rufenacht,
  • Marion Roesch ,
  • Emmanuel Simon,
  • Marc Puyraveau ,
  • Frederic Mauny ,
  • Nicolas Mottet
Louise Lucot-Royer
Hospital Jean Minjoz

Corresponding Author:[email protected]

Author Profile
Charline Bertholdt
Maternite universitaire CHRU de Nancy
Author Profile
Solene Marty-Quinternet
Hospital Jean Minjoz
Author Profile
Jean Paul Bory
Reims Champagne-Ardenne University
Author Profile
Christine Devalland
Hôpital Nord Franche-Comté
Author Profile
Margaux Canaguier
Hôpital Nord Franche-Comté
Author Profile
Camille Coppola
Haute-Saône Hospital Group
Author Profile
Marie-Laure Eszto
CHR Metz-Thionville
Author Profile
Edgar Montoya Ramirez
Groupe Hospitalier de la Region de Mulhouse et Sud Alsace
Author Profile
Sandrine Reviron
Centre Hospitalier de Lons-le-Saunier
Author Profile
Didier Riethmuller
Grenoble Alpes University Hospital
Author Profile
Emma Rufenacht
Centre Hospitalier de Pontarlier
Author Profile
Marion Roesch
Regional Hospital Centre Metz-Thionville
Author Profile
Emmanuel Simon
CHU Dijon
Author Profile
Marc Puyraveau
Hôpital Jean Minjoz
Author Profile
Frederic Mauny
Hôpital Jean Minjoz
Author Profile
Nicolas Mottet
CHU Besancon
Author Profile

Abstract

Objective: To quantify the transplacental transmission of SARS-CoV-2 and antibodies in pregnant women and their new-borns according to the trimester of maternal infection. Design: This was a prospective observational multicentre study including pregnant women with positivity for SARS-CoV-2 by reverse transcription–polymerase chain reaction (RT‒PCR) or positivity by serology from April to December 2020. The study was designed to perform a systematic collection of mother/new-born dyad samples at birth. Setting: Eleven maternity wards in Eastern France Population: Pregnant women with confirmed COVID-19 infection during pregnancy and their new-borns. Methods: The SARS-CoV-2 viral load was measured by RT‒PCR. IgG and IgM antibodies to the receptor-binding domain of the SARS-CoV-2 spike protein were measured by enzyme-linked immunosorbent assay. Antibody concentrations and transplacental transfer ratios were analysed according to the term of maternal infection. Main Outcome Measure: SARS-CoV-2 viral load in maternal plasma or respiratory fluids and umbilical cord plasma and quantification of anti-SARS-CoV-2 antibody transfer. Results: Among 165 dyads enrolled, one congenital infection was confirmed (n=1 (0.63%) IC95% [0.02%; 3.48%]). Among 165 maternal sera tested, 107 (64.8%) were positive for IgG with a concentration > 25.6 BAU/ml. The average placental transfer ratio was 1.27 (95% CI [0.69–2.89]). The transfer ratio increased with increasing time between the onset of maternal infection and delivery (P value = 0.0001). Conclusions: We confirmed very low SARS-CoV-2 transplacental transmission of less than 1%. Transmission of antibodies is more likely when the infection occurs in the first or second trimester of pregnancy.